Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials
AbstractLytic enzymes encoded by bacteriophages have been intensively explored as alternative agents for combating bacterial pathogens in different contexts. The antibacterial character of these enzymes (enzybiotics) results from their degrading activity towards peptidoglycan, an essential component of the bacterial cell wall. In fact, phage lytic products have the capacity to kill target bacteria when added exogenously in the form of recombinant proteins. However, there is also growing recognition that the natural bactericidal activity of these agents can, and sometimes needs to be, substantially improved through manipulation of their functional domains or by equipping them with new functions. In addition, often, native lytic proteins exhibit features that restrict their applicability as effective antibacterials, such as poor solubility or reduced stability. Here, I present an overview of the engineering approaches that can be followed not only to overcome these and other restrictions, but also to generate completely new antibacterial agents with significantly enhanced characteristics. As conventional antibiotics are running short, the remarkable progress in this field opens up the possibility of tailoring efficient enzybiotics to tackle the most menacing bacterial infections. View Full-Text
Share & Cite This Article
São-José, C. Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials. Antibiotics 2018, 7, 29.
São-José C. Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials. Antibiotics. 2018; 7(2):29.Chicago/Turabian Style
São-José, Carlos. 2018. "Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials." Antibiotics 7, no. 2: 29.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.